Endoscopy of the esophagus in gastroesophageal reflux disease: Are we losing sight of symptoms? Another perspective

Diseases of the Esophagus

Volumn 22, Issue 5, 2009, Pages 461-466

  Sharma, Prateek ^a   Chey, William ^b   Hunt, Richard ^c   Laine, Loren ^d   Malfertheiner, Peter ^e   Wani, Sachin ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Barrett's esophagus; Endoscopy; Erosive esophagitis; Gastroesophageal reflux disease; Non erosive reflux disease

Indexed keywords

ARTICLE; CLINICAL CLASSIFICATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENDOSCOPY; ESOPHAGITIS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; MEDICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY;

ANTACIDS; BARRETT ESOPHAGUS; DECISION MAKING; DIAGNOSIS, DIFFERENTIAL; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PATIENT CARE PLANNING; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; RESEARCH DESIGN;

EID: 67949120532     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00934.x     Document Type: Article

References (31)

1. Kulig M, Nocon M, Vieth M et al. Risk factors of gastroesophageal reflux disease: Methodology and first epidemiological results of the proGERD study. J Clin Epidemiol 2004; 57 (6): 580-9.
2. Shaheen N J, Hansen R A, Morgan D R et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128-38.
3. Liu J Y, Woloshin S, Laycock W S, Rothstein R I, Finlayson S R, Schwartz L M. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med 2004; 164: 2058-64.
4. Heading R C. Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol Suppl 1999; 231: 3-8.
5. Dent J, El-Serag H B, Wallander M A, Johansson S. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005; 54: 710-7.
6. Talley N J, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy negative heartburn: Reliability and severity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998-2004.
7. McDougall N I, Johnston B T, Kee F, Collins J S, McFarland R J, Love A H. Natural history of reflux oesophagitis: A 10 year follow up of its effect on patients symptomatology and quality of life. Gut 1996; 38: 481-6.
8. Dent J. Definitions of reflux disease and its separation from dyspepsia. Gut 2002; 50 (Suppl 4): Iv17-20.
9. Dent J, Brun J, Fendrick A M et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999; 44 (Suppl 2): S1-16.
10. Vakil N, van Zanten S V, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
11. Falk G W, Fennerty B F, Rothstein R I. AGA institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131 (4): 1315-36.
12. Locke G R III, Talley N J, Fett S L, Zinsmeister A R, Melton L J III. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112 (5): 1448-56.
13. Fass R, Ofman J J. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
14. Kahrilas P J. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S15-23.
15. Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85.
16. Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease (GORD) in primary care-an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
17. Quigley E M. Non-erosive reflux disease: Part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 (Suppl 1): S13-8.
18. Quigley E M. The spectrum of GERD: A new perspective. Drugs Today 2005; 41 (Suppl B): 3-6.
19. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: Proton pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005; 22: 79-94.
20. Quigley E M. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): Overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004; 18 (4): 695-706.
21. Shaw M. Diagnostic utility of reflux disease symptoms. Gut 2004; 53 (Suppl IV): Iv25-27.
22. Bardhan K D, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. Evaluation of GERD symptoms during therapy. Part I: development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 229-37.
23. Monnikes H, Bardhan K D, Stanghellini V, Berghöfer P, Bethke T D, Armstrong D. Evaluation of GERD symptoms during therapy. Part II: psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 238-44.
24. Van Pinzteren B, Numans M, Bonis P, Lau J. Short-term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001: CD002095.
25. National Institute for Clinical Excellence. Dyspepsia: Management of dyspepsia in adults in primary care. Clinical guideline 17, 2004 Aug. [Cited September 17, 2008] Available from URL: http://www.nice.org.uk/ CG017NICEguideline
26. Vakil N. How valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005; 22 (Suppl 1): 64-9.
27. Bardhan K D, Muller-Lissner S, Bigard M A et al. Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502-7.
28. Lind T, Havelund T, Carlsson R et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
29. Dean B B, Gano A D, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
30. Numans M E, Lau J, de Wit N J, Bonis P A. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: A meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-27.
31. Nojkov B, Chey W D, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: The influence of co-morbid IBS and psychological disease. Gastroenterology 2005; 128: AB416.